drugset / Trial / NCT04417062
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Phase 2
Active not recruiting
63 enrolled
Dana-Farber Cancer Institute
AstraZeneca · collabOsteosarcoma Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: * Olaparib * Ceralasertib
Timeline
- Start
- 2020-11-24
- Primary completion
- 2025-06-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | — | Oral |
| Subject | Olaparib | Small molecule | — | Oral |